Gyre Therapeutics Inc (NASDAQ:GYRE)
| 20.74 Delayed Data As of 3:59pm ET |  +2.46 / +13.46%Today’s Change | 2.83 Today|||52-Week Range 27.39 | +162.12% Year-to-Date |
Latest GYRE News | Press Releases
| These 3 Biotech Stocks More Than Doubled in November. Can They Fly Even Higher in 2024? Dec 02 / MotleyFool.com - Paid Partner Content |
Today’s Trading
| Previous close | 18.28 |
| Today’s open | 18.01 |
| Day’s range | 18.01 - 20.77 |
| Volume | 6,688 |
| Average volume (3 months) | 58,508 |
| Market cap | $1.7B |
Data as of 3:59pm ET, 12/08/2023
Growth & Valuation
| Earnings growth (last year) | +90.90% |
| Earnings growth (this year) | -- |
| Earnings growth (next 5 years) | +15.00% |
| Revenue growth (last year) | -89.18% |
| P/E ratio | 75.0 |
| Price/Sales | 20.96 |
| Price/Book | -- |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| MORMorphoSys AG | +0.18 | +2.63% |
| MRUSMerus NV | -0.85 | -3.43% |
| SRRKScholar Rock Holding... | +0.70 | +3.99% |
| NVAXNovavax Inc | +0.04 | +0.72% |
Data as of 3:59pm ET, 12/08/2023
Financials
| Next reporting date | -- |
| EPS forecast (this quarter) | -- |
| Annual revenue (last year) | $794.0K |
| Annual profit (last year) | -$8.2M |
| Net profit margin | -1,038.04% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters San Diego, California |
Forecasts
